Travere Therapeutics, Inc. — Form 10-Q
Filed November 2, 2026 · analyzed by the Periodic Agent
10-Q
— Neutral
significance 2/100
What the filing says
Eric Dube (CEO) and Christopher Cline (CFO) certified on November 2, 2026, that the Q3 2026 10-Q fairly presents Travere's financial condition and results of operations, and that disclosure controls and internal controls over financial reporting are effective. No material weaknesses, deficiencies, or management fraud were disclosed.
Why this rating
Routine Sarbanes-Oxley certification exhibits; standard quarterly filing requirement with no substantive operational, financial, or control changes disclosed.
See more from November 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.